Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS study.
Antonios BayasUlrich MansmannBegum Irmak ÖnVerena S HoffmannAchim BertheleMark MühlauMarkus C KowarikMarkus KrumbholzMakbule SenelVerena SteuerwaldMarkus NaumannJulia HartbergerMartin KerschensteinerEva OswaldChristoph RuschilUlf ZiemannHayrettin TumaniIoannis VardakasFady AlbashitiFrank KramerIñaki Soto-ReyHelmut SpenglerGerhard MayerHans Armin KestlerOliver KohlbacherMarlien HagedornMartin BoekerKlaus KuhnStefan BuchkaFlorian KohlmayerJan S KirschkeLars BehrensHanna ZimmermannBenjamin BenderNico SollmannJoachim HavlaBernhard Hemmernull nullPublished in: Neurological research and practice (2024)
Clinical cohorts provide the infrastructure to discover and to validate relevant disease-specific findings. A successful validation of the MS-TDS will add a new clinical decision tool to the armamentarium of practicing MS neurologists from which newly diagnosed MS patients may take advantage. Trial registration ProVal-MS has been registered in the German Clinical Trials Register, `Deutsches Register Klinischer Studien` (DRKS)-ID: DRKS00014034, date of registration: 21 December 2018; https://drks.de/search/en/trial/DRKS00014034.